The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma

• Autors principals: Vivian Jiang (Autor), William Lee (Autor), Tianci Zhang (Autor), Alexa Jordan (Autor), Fangfang Yan (Autor), Qingsong Cai (Autor), Joseph McIntosh (Autor), Jovanny Vargas (Autor), Yang Liu (Autor), Michael Wang (Autor)
• Format: Llibre
• Publicat: BMC, 2024-06-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Inhibitors of Bruton's tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell lymphoma (MCL). However, clinical relapses following BTKi and CD19-directed CAR-T treatments...